Tirzepatide vs Ozempic and Wegovy: The Brand Comparison
Tirzepatide (Mounjaro / Zepbound) compared to Novo Nordisk's two most popular semaglutide brands. Trial data, real cost, and the practical differences.
01 The 30-second comparison
| Feature | Tirzepatide | Ozempic | Wegovy |
|---|---|---|---|
| Active ingredient | Tirzepatide | Semaglutide | Semaglutide |
| Mechanism | GLP-1 + GIP | GLP-1 only | GLP-1 only |
| Maker | Eli Lilly | Novo Nordisk | Novo Nordisk |
| FDA indication | T2D + weight + OSA | Type 2 diabetes | Weight management + CV |
| Max dose | 15 mg/wk | 2.0 mg/wk | 2.4 mg/wk |
| Brand monthly | $1,086–$1,135 | $1,000 | $1,349 |
| Avg. weight loss | 20.9% (15 mg) | Not approved | 14.9% (2.4 mg) |
02 Tirzepatide vs Ozempic
Ozempic contains semaglutide, the same active ingredient as Wegovy but at lower doses (0.25 mg → 2.0 mg weekly) and labeled for type 2 diabetes, not weight management. It's the most-prescribed semaglutide brand and the one most casually associated with celebrity weight loss in the press — even though Ozempic is technically a diabetes drug.
Compared to tirzepatide:
- Mechanism: Ozempic is GLP-1 only. Tirzepatide adds GIP for greater appetite suppression and weight loss.
- Approved use: Ozempic is FDA-approved for type 2 diabetes (and cardiovascular risk reduction in T2D with CV disease). It is not FDA-approved for weight loss, though it's widely prescribed off-label. Tirzepatide is approved for both diabetes (Mounjaro) and weight loss (Zepbound).
- Weight loss: Off-label Ozempic at max dose (2.0 mg) produces about 6 kg (13 lb) loss. Tirzepatide at max dose (15 mg) produces about 11–22 kg (24–48 lb) loss depending on the trial population.
- Cost: Ozempic retails for about $1,000/month, slightly less than Mounjaro ($1,135/month). With insurance for diabetes, both are typically $25–$75/month.
For diabetes
SURPASS-2 directly compared tirzepatide and semaglutide head-to-head in patients with type 2 diabetes. Tirzepatide produced larger HbA1c reductions and roughly 2× the weight loss at the doses studied. Either is a reasonable diabetes choice; tirzepatide tends to win when weight loss is also a goal.
For weight loss
If weight loss is your main goal, the comparison should really be tirzepatide (Zepbound) vs semaglutide (Wegovy) — using Ozempic off-label for weight loss makes less sense in 2026 when both Zepbound and Wegovy are approved for the indication.
03 Tirzepatide vs Wegovy
Wegovy is the weight-loss brand of semaglutide, with the higher 2.4 mg max dose specifically optimized for weight management. It has been the dominant brand in obesity medicine since 2021 — until Zepbound launched in late 2023.
| Feature | Zepbound (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| FDA approval | November 2023 | June 2021 |
| Mechanism | GLP-1 + GIP | GLP-1 only |
| Max dose | 15 mg/wk | 2.4 mg/wk |
| Avg. weight loss (max dose, 68–72 wks) | 20.9% | 14.9% |
| Retail price/mo | $1,086 | $1,349 |
| Manufacturer-direct/mo | $349–$599 (LillyDirect) | $499 (NovoCare) |
| Sleep apnea approval | Yes (Dec 2024) | No |
| Cardiovascular approval | Yes (Mar 2024) | Yes (Mar 2024) |
On nearly every dimension that matters to a weight-loss patient, Zepbound has caught up to or surpassed Wegovy: more weight loss in trials, lower brand-name cost, and additional approvals (sleep apnea). The main reason to choose Wegovy in 2026 is if you've been doing well on it already and your insurance covers it but not Zepbound.
04 Cost comparison across all four
| Drug | Brand monthly | Manufacturer self-pay | Compounded telehealth | Insured copay |
|---|---|---|---|---|
| Mounjaro (tirz) | $1,135 | $349–$599 (Lilly Direct vials) | $199–$329 | $25–$75 |
| Zepbound (tirz) | $1,086 | $349–$599 (Lilly Direct vials) | $199–$329 | $25–$75 |
| Ozempic (sema) | $1,000 | $499 (NovoCare for diabetes) | $179–$299 | $25–$75 |
| Wegovy (sema) | $1,349 | $499 (NovoCare) | $179–$299 | $0–$25 |
For self-pay patients, compounded tirzepatide is the cheapest tirzepatide option. For insured patients, the lowest absolute price usually comes from manufacturer copay assistance — but both Lilly (Zepbound) and Novo (Wegovy) restrict copay cards to commercially insured patients with coverage.
05 Switching from Ozempic or Wegovy to tirzepatide
The protocol is the same for either source:
- Stop semaglutide for 1 full week.
- Start tirzepatide at the equivalent low end (typically 2.5 or 5 mg, regardless of your prior semaglutide dose).
- Re-titrate by stepping up every 2–4 weeks based on tolerance.
- Don't bridge or overlap. Switch cleanly.
Use the dose conversion calculator to estimate a starting dose based on your current semaglutide dose.
06 Which should you choose?
Tirzepatide wins if…
- Maximum weight loss is the priority
- You've plateaued on semaglutide
- You also need OSA treatment
- You want the cheapest brand-name weight-loss option
- Cost-conscious self-pay (Zepbound < Wegovy at retail)
Semaglutide may be better if…
- It's already covered by your insurance and tirzepatide isn't
- You're tolerating it well and hitting your goals
- You want an oral option (Rybelsus is oral semaglutide)
- You're sensitive to GI side effects (slightly different profile)
Get tirzepatide online.
Whether you're new to GLP-1s or switching from Ozempic or Wegovy, telehealth providers handle the transition. Same molecule as Mounjaro/Zepbound, lower price.
See Provider Options→07 Tirzepatide vs Ozempic / Wegovy FAQ
No. Tirzepatide and Ozempic are different molecules. Tirzepatide (Mounjaro/Zepbound) is a GLP-1 + GIP dual agonist made by Eli Lilly. Ozempic contains semaglutide, a GLP-1-only agonist made by Novo Nordisk. Both are weekly injectable medications, both treat type 2 diabetes, but they are different drugs.
Tirzepatide. In SURPASS-2 (head-to-head trial in T2D), tirzepatide 15 mg produced about 11.2 kg (25 lb) of weight loss vs 5.7 kg (12.5 lb) for semaglutide 1.0 mg over 40 weeks — roughly 2× more loss. For weight management specifically, the comparison is Zepbound (tirzepatide) vs Wegovy (semaglutide 2.4 mg), where tirzepatide still leads (20.9% vs 14.9%).
No. Wegovy contains semaglutide, not tirzepatide. They are different molecules. Wegovy is the weight-loss brand of semaglutide; Zepbound is the weight-loss brand of tirzepatide. Both are made for weight management but by different companies (Novo Nordisk vs Eli Lilly).
Brand-name Zepbound (tirzepatide) costs about $1,086/month at retail; Wegovy (semaglutide) costs about $1,349/month. Tirzepatide is roughly $260/month cheaper at the brand level, in addition to producing more weight loss. Compounded versions of both drugs are similar in price ($179–$329/month).
Yes. Mounjaro (the diabetes brand of tirzepatide) is roughly $1,135/month at retail. Ozempic (the diabetes brand of semaglutide) is roughly $1,000/month. So Ozempic is cheaper at the brand level. Both are widely covered by commercial insurance for type 2 diabetes — copays typically $25–$75/month with prior authorization.
Yes, this is a common transition. Most prescribers stop Ozempic for one full week, then start tirzepatide (Mounjaro for diabetes or Zepbound for weight loss) at a low equivalent dose — typically 2.5–5 mg, regardless of how much Ozempic you were taking. Re-titrate weekly to gauge tolerance. See our dose converter.
Related
vs Semaglutide (deeper) →
The molecule-level comparison with the dose conversion calculator.
vs Retatrutide →
The next-generation triple agonist now in late-stage trials.
Cost calculator →
Live monthly pricing across every provider and brand.